Please use this identifier to cite or link to this item:
|Title:||Combination chemotherapy and photodynamic therapy with Fab' fragment targeted HPMA copolymer conjugates in human ovarian carcinoma cells|
University of Utah
|Keywords:||Biochemistry, Genetics and Molecular Biology;Pharmacology, Toxicology and Pharmaceutics|
|Citation:||Molecular Pharmaceutics. Vol.5, No.5 (2008), 696-709|
|Abstract:||The biological activities of sequential combinations of anticancer drugs, SOS thiophene (SOS) and mesochlorin e6 monoethylenediamine (Mce6), in the form of free drugs, nontargeted N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer - drug conjugates, P-GFLG-Mce6 and P-GFLG-SOS (P is the HPMA copolymer backbone and GFLG is the glycylphenylalanylleucylglycine spacer), and Fab′-targeted HPMA copolymer - drug conjugates, P-(GFLG-Mce6)-Fab′ and P-(GFLG-SOS)-Fab′ (Fab′ from OV-TL 16 antibodies complementary to CD47), were evaluated against human ovarian carcinoma OVCAR-3 cells. Mce6, SOS, P-GFLG-Mce6, P-GFLG-SOS, P-(GFLG-Mce6)-Fab′, and P-(GFLG-SOS)-Fab′, when used as single agents or in binary combination, exhibited cytotoxic activities against OVCAR-3 cells, as determined using a modified MTT assay. The binding and internalization of P-(GFLG-Mce6)-Fab′ and P-(GFLG-SOS)-Fab′ by OVCAR-3 cells were visualized by confocal microscopy and flow cytometry. The results confirmed an enhanced biorecognition by OVCAR-3 cells of Fab′-targeted HPMA copolymer conjugates over nontargeted conjugates. The median-effect analysis and the determination of the combination index (CI) were used to describe the drug interaction and quantify the synergism, antagonism, or additivity in anticancer effects. The sequential combinations of SOS+Mce6 and P-GFLG-SOS+P-GFLG-Mce6 displayed very strong synergism to synergism in the entire range of cell inhibition levels (fa = 0.5 - 0.95). The P-(GFLG-SOS)-Fab′+P-(GFLG-Mce6)- Fab′ exhibited a strong synergism for fa values up to about 0.85, but showed synergistic effect and nearly additive effect at fa = 0.9 and 0.95, respectively. These observations support the continuation of in vivo investigations of these conjugates for the treatment of ovarian cancer. © 2008 American Chemical Society.|
|Appears in Collections:||Scopus 2006-2010|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.